{"id":"placebo-matched-to-mtx","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2074706","moleculeType":"Small molecule","molecularWeight":"466.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not interact with any biological molecules or systems. It is used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"This drug is a placebo, meaning it has no active therapeutic effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:46.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Matched to Methotrexate (MTX) in clinical trials"}]},"trialDetails":[{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT06671054","phase":"PHASE2","title":"A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2024-10-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":240},{"nctId":"NCT06800157","phase":"PHASE2","title":"Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","startDate":"2023-02-27","conditions":"Arthritis, Rheumatoid","enrollment":72},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT05604885","phase":"PHASE2","title":"A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"SynAct Pharma Aps","startDate":"2022-11-30","conditions":"Rheumatoid Arthritis","enrollment":125},{"nctId":"NCT02305849","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-07-25","conditions":"Rheumatoid Arthritis","enrollment":519},{"nctId":"NCT05279417","phase":"PHASE2","title":"ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2022-02-01","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT01751776","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-12-18","conditions":"Arthritis, Rheumatoid, Healthy","enrollment":107},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT04247815","phase":"PHASE2","title":"Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2020-03-16","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03813199","phase":"PHASE2","title":"Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-07-04","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02079948","phase":"PHASE2","title":"Inflammation Control For Elders: ICE Study","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2014-02","conditions":"Inflammation, Aging","enrollment":""},{"nctId":"NCT03163966","phase":"PHASE2","title":"A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Rottapharm Biotech","startDate":"2017-10-05","conditions":"Rheumatoid Arthritis, DMARD-naive and Early Disease Patients","enrollment":248},{"nctId":"NCT01651936","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-08-29","conditions":"Rheumatoid Arthritis","enrollment":56},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT02886728","phase":"PHASE3","title":"Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-08","conditions":"Rheumatoid Arthritis","enrollment":1252},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03275025","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2017-04-01","conditions":"Rheumatoid Arthritis","enrollment":116},{"nctId":"NCT01894516","phase":"PHASE2","title":"Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2013-10-08","conditions":"Rheumatoid Arthritis","enrollment":287},{"nctId":"NCT00406419","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2006-12-27","conditions":"Rheumatoid Arthritis","enrollment":1015},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT02831855","phase":"PHASE4","title":"Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-09-01","conditions":"Rheumatoid Arthritis","enrollment":694},{"nctId":"NCT01303874","phase":"PHASE4","title":"Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis","enrollment":112},{"nctId":"NCT01569152","phase":"PHASE2","title":"Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-22","conditions":"Rheumatoid Arthritis (RA)","enrollment":82},{"nctId":"NCT02312219","phase":"","title":"PET/CT Imaging Companion Study To ACTG A5314","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-11","conditions":"HIV, Inflammation, Atherosclerosis","enrollment":35},{"nctId":"NCT02379091","phase":"PHASE2","title":"Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-12-17","conditions":"Rheumatoid Arthritis","enrollment":108},{"nctId":"NCT01855789","phase":"PHASE3","title":"A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-07","conditions":"Rheumatoid Arthritis","enrollment":718},{"nctId":"NCT01217814","phase":"PHASE2","title":"Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT01758198","phase":"PHASE4","title":"Abatacept Post-marketing Clinical Study in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-04-11","conditions":"Rheumatoid Arthritis","enrollment":405},{"nctId":"NCT01034137","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":317},{"nctId":"NCT01142726","phase":"PHASE3","title":"Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":511},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT01164579","phase":"PHASE2","title":"Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":109},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556},{"nctId":"NCT00487825","phase":"PHASE2","title":"Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Rheumatoid Arthritis","enrollment":78},{"nctId":"NCT00903383","phase":"PHASE2","title":"Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2009-07","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT00760968","phase":"PHASE2","title":"Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-08","conditions":"Arthritis, Rheumatoid","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Matched to MTX","genericName":"Placebo Matched to MTX","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a placebo, meaning it has no active therapeutic effect. Used for Matched to Methotrexate (MTX) in clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}